Nanjing Immunophage Biotech Co., Ltd

Nanjing Immunophage Biotech is a Chinese biotech company with limited publicly available information, making due diligence challenging for potential US partners. The company appears to focus on immunotherapy based on its name, but pipeline details, financial status, and management team remain unclear. BIOSECURE risk appears low as the company is not currently designated, but ongoing monitoring is essential given evolving regulations. Limited transparency suggests early-stage engagement should focus on information gathering and relationship building.

Structure: Corporate structure details are not publicly available, requiring direct engagement to understand ownership layers, VIE arrangements, or holding company structures. The lack of transparency around corporate structure presents a red flag for due diligence and may indicate either early-stage company status or intentional opacity.